Oppenheimer & Co’s Mereo BioPharma MREO Stock Holding History

Oppenheimer & Co’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,000	Closed	-$18.1K	–	1430
2023 Q3	$18.1K	Hold	14,000	–	–	﹤0.01%	1366
2023 Q2	$18.5K	Sell	14,000 -10,000	-42%	-$11.6K	﹤0.01%	1403
2023 Q1	$17K	Hold	24,000	–	–	﹤0.01%	1367
2022 Q4	$18K	Sell	24,000 -2,000	-8%	-$1.64K	﹤0.01%	1334
2022 Q3	$22K	Hold	26,000	–	–	﹤0.01%	1341
2022 Q2	$29K	Buy	26,000 +6,000	+30%	+$4.65K	﹤0.01%	1379
2022 Q1	$22K	Hold	20,000	–	–	﹤0.01%	1456
2021 Q4	$32K	Buy	20,000 +1,000	+5%	+$2K	﹤0.01%	1476
2021 Q3	$46K	Buy	+19,000	New	+$50.3K	﹤0.01%	1471

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Oppenheimer & Co's MREO Position: Q4 2023 in Review

Oppenheimer & Co sold out of Mereo BioPharma (MREO) in Q4 2023, closing a stake of 14,000 shares — an estimated $18.1K sold.

Oppenheimer & Co first reported a position in MREO in Q3 2021 and held it in 9 quarters. The position peaked at $46K in Q3 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q4 2023.

Oppenheimer & Co reported no remaining Mereo BioPharma position as of Q4 2023 after selling out during the quarter.
Oppenheimer & Co sold 14,000 Mereo BioPharma shares in Q4 2023, an estimated $18.1K.
Oppenheimer & Co first reported a position in Mereo BioPharma in Q3 2021 and held it in 9 quarters.
Oppenheimer & Co's Mereo BioPharma position peaked at $46K in Q3 2021.
64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2023.

Based on Oppenheimer & Co's 13F filing for Q4 2023, filed 13 Feb 2024.